[ASMB] Assembly Biosciences, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 100.97 M

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 11.78 Change: 0.03 (0.26%)
Ext. hours: Change: 0 (0%)

chart ASMB

Refresh chart

Strongest Trends Summary For ASMB

ASMB is in the medium-term down -10% below S&P in 4 months and down -34% in 7 months. In the long-term down -73% below S&P in 2 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Assembly Biosciences, Inc. provides development and commercialization of gastrointestinal products in the United States. The company is developing two late-stage development product candidates, including VEN 307, a diltiazem cream for the relief of pain associated with anal fissures; and VEN 308, a phenylephrine gel for the treatment of fecal incontinence associated with ileal pouch anal anastomosis. It is also involved in the development of VEN 310 as a colonic delivery mechanism, which is a PH sensitive system to deliver bacteria, complex proteins, viral antigens, small molecules, and other treatments. The company was formerly known as Ventrus Biosciences Inc. and changed its name to Assembly Biosciences, Inc. in July, 2014. Assembly Biosciences, Inc. was founded in 2005 and is based in New York, New York.

Fundamental Ratios
Shares Outstanding17.23 M EPS-2.74 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-7.94
P/E To EPS Growth P/S P/BV0.81 Price/Cash Per Share
Price/Free Cash Flow-6.68 ROA-19.42% ROE-21.56% ROI
Current Ratio45.27 Quick Ratio Long Term Debt/Equity Debt Ratio0.02
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities70.67 M Cash From Investing Activities-30 K Cash From Operating Activities-3.67 M Gross Profit
Net Profit-7.14 M Operating Profit-7.2 M Total Assets138.35 M Total Current Assets96.34 M
Total Current Liabilities2.13 M Total Debt Total Liabilities13.73 M Total Revenue
Technical Data
High 52 week44.23 Low 52 week11.86 Last close14 Last change0%
RSI57.33 Average true range0.84 Beta0.87 Volume30.34 K
Simple moving average 20 days7.77% Simple moving average 50 days2.4% Simple moving average 200 days-25.55%
Performance Data
Performance Week15.51% Performance Month6.06% Performance Quart-16.77% Performance Half-37.75%
Performance Year-67.14% Performance Year-to-date-38.11% Volatility daily4.83% Volatility weekly10.79%
Volatility monthly22.11% Volatility yearly76.6% Relative Volume234.77% Average Volume270.13 K
New High New Low


2019-09-15 09:16:24 | Investors Who Bought Assembly Biosciences NASDAQ:ASMB Shares A Year Ago Are Now Down 67%

2019-08-09 16:30:00 | Assembly Biosciences Reports Inducement Grants under NASDAQ Listing Rule 5635c4

2019-08-07 08:00:00 | Assembly Biosciences Announces Appointment of John McHutchison, AO, MD, as President and Chief Executive Officer

2019-08-05 19:25:11 | Assembly Biosciences ASMB Reports Q2 Loss, Lags Revenue Estimates

2019-08-05 16:05:00 | Assembly Biosciences Reports Second Quarter 2019 Financial Results and Recent Highlights

2019-07-17 13:08:50 | Does The Assembly Biosciences, Inc. NASDAQ:ASMB Share Price Tend To Follow The Market?

2019-06-27 07:05:00 | Assembly Biosciences Announces First Patient Dosed with ABI-M201 in Phase 1b Clinical Trial for Mildly to Moderately Active Ulcerative Colitis

2019-06-25 16:05:00 | Assembly Biosciences Announces Participation in the Microbiome Movement Drug Development Summit

2019-06-21 07:05:00 | Assembly Biosciences Announces Presentation at International Association for the Study of the Liver Congress and Update on HBV Program in China

2019-06-14 16:41:49 | Here’s What Hedge Funds Think About Assembly Biosciences Inc ASMB

2019-05-21 15:30:13 | Read This Before Selling Assembly Biosciences, Inc. NASDAQ:ASMB Shares

2019-05-09 19:45:11 | Assembly Biosciences ASMB Reports Q1 Loss, Tops Revenue Estimates

2019-05-09 18:37:27 | Assembly Biosciences: 1Q Earnings Snapshot

2019-05-09 16:05:00 | Assembly Biosciences Reports First Quarter 2019 Financial Results and Recent Highlights

2019-05-09 13:33:50 | Here’s What Hedge Funds Think About Assembly Biosciences Inc ASMB

2019-05-03 07:49:09 | The Daily Biotech Pulse: Obseva Reports Positive Endometriosis Drug Trial, Assembly Biosciences Execs Depart, Coherus Settles With Amgen

2019-04-29 10:31:02 | Analysts Estimate Assembly Biosciences ASMB to Report a Decline in Earnings: What to Look Out for

2019-04-22 16:51:05 | Development Veteran Steven J. Knox Joins Assembly Biosciences as Senior Vice President, Clinical Development

2019-04-15 13:37:00 | Here's Why Assembly Biosciences Is Slipping Today

2019-04-13 12:00:00 | Assembly Biosciences Presents Interim Data from Two Phase 2a Studies of ABI-H0731 in HBV-Infected Subjects in a Late-Breaker Oral Session at EASL 2019

2019-04-11 07:05:00 | Assembly Biosciences Presents Data Highlighting Next-Generation HBV Core Protein Inhibitors at EASL 2019

2019-04-02 07:07:00 | 4 Biotech Stocks With Major Catalysts in April

2019-03-27 07:05:00 | Assembly Biosciences Announces Multiple Abstracts Highlighting HBV Core Inhibitor Portfolio Accepted for Oral and Poster Presentations at EASL 2019

2019-03-13 07:05:00 | Assembly Biosciences to Participate in the Jefferies 2019 HBV Summit

2019-03-06 13:35:11 | If You Had Bought Assembly Biosciences Stock Three Years Ago, You Could Pocket A 261% Gain Today

2019-02-28 17:00:00 | Assembly Biosciences Reports Fourth Quarter and Year End 2018 Financial Results

2019-02-19 17:47:10 | Generic-Drugs Outlook: Price Erosion to Hurt Near-Term Prospects

2019-02-13 08:25:00 | Market Trends Toward New Normal in Brighthouse Financial, BioMarin Pharmaceutical, EZCORP, Assembly Biosciences, A-Mark Precious Metals, and American Public Education — Emerging Consolidated Expectations, Analyst Ratings

2019-01-31 09:30:02 | Mylan MYL Jumps: Stock Rises 7.1%

2019-01-15 12:24:55 | Assembly Biosciences, Inc. NASDAQ:ASMB Insiders Increased Their Holdings

2019-01-07 07:00:00 | Assembly Biosciences Announces Completion of Enrollment in Two Phase 2a Studies with ABI-H0731 for Chronic Hepatitis B Virus

2018-12-16 09:04:00 | Here is What Hedge Funds Think About Assembly Biosciences Inc ASMB

2018-12-03 08:52:01 | Amphastar Pharmaceuticals AMPH Catches Eye: Stock Jumps 6.7%

2018-11-30 08:17:09 | Should You Worry About Assembly Biosciences Inc’s NASDAQ:ASMB CEO Pay?

2018-11-12 07:05:00 | Assembly Biosciences Presents Final Results of Phase 1b Study of ABI-H0731 at 2018 AASLD

2018-11-08 11:10:04 | Assembly Biosciences ASMB Reports Q3 Loss, Tops Revenue Estimates

2018-11-08 10:04:31 | Assembly Biosciences: 3Q Earnings Snapshot

2018-11-08 07:00:00 | Assembly Biosciences Announces Third Quarter 2018 Financial Results and Provides HBV Program Update

2018-10-31 10:32:02 | Analysts Estimate Assembly Biosciences ASMB to Report a Decline in Earnings: What to Look Out for

2018-10-31 07:00:00 | Assembly Biosciences Announces November Conference Participation

2018-10-16 07:36:37 | Report: Developing Opportunities within The Ensign Group, Forterra, Inc., Audentes Therapeutics, Assembly Biosciences, Capital Senior Living, and Myomo — Future Expectations, Projections Moving into 2018

2018-10-08 15:16:30 | Recent Assembly Biosciences Weakness Provides Attractive Entry Point, B Riley FBR Says In Upgrade

2018-10-02 07:05:00 | Assembly Biosciences Announces Oral Presentation at 2018 AASLD

2018-10-01 08:43:56 | Shareholders Should Check The Ownership Structure Of Assembly Biosciences Inc NASDAQ:ASMB

2018-08-28 07:05:00 | Assembly Biosciences to Present at Upcoming Investor Conferences

2018-08-16 07:35:00 | Analysis: Positioning to Benefit within Amtech, NL Industries, Dova Pharmaceuticals, Sientra, Dorian LPG, and Assembly Biosciences — Research Highlights Growth, Revenue, and Consolidated Results

2018-08-08 20:25:12 | Assembly Biosciences ASMB Reports Q2 Loss, Misses Revenue Estimates

2018-08-08 19:19:28 | Assembly Biosciences: 2Q Earnings Snapshot

2018-08-08 16:05:00 | Assembly Biosciences Announces Second Quarter 2018 Financial Results

2018-07-25 07:05:00 | Assembly Biosciences Announces FDA Fast Track Designation Granted to ABI-H0731 for the Treatment of Hepatitis B Virus Infection